Mercredi, 26 Juillet 2017
Latest news
Main » Analysts Recommended this Stock: Verastem, Inc. (VSTM)

Analysts Recommended this Stock: Verastem, Inc. (VSTM)

17 Juillet 2017

D E Shaw owns 0% invested in Verastem Inc (NASDAQ:VSTM) for 392,736 shares. Renaissance Technologies LLC now owns 1,022,200 shares of the biopharmaceutical company's stock worth $1,145,000 after buying an additional 122,600 shares in the last quarter. The company discovers, researches, and develops new medicines for the treatment of major cancers such as breast cancer. Verastem had 20 analyst reports since September 9, 2015 according to SRatingsIntel.

Several equities analysts recently issued reports on VSTM shares. HC Wainwright lifted their target price on shares of Verastem from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 24th. Cann reiterated a "buy" rating and set a $2.00 target price on shares of Verastem in a research report on Thursday, May 11th. Its last month's stock price volatility remained 2.34% which for the week stands at 2.57%. Jefferies Group LLC restated a "hold" rating and set a $1.50 target price on shares of Verastem in a research report on Wednesday, June 28th. Oppenheimer maintained the stock with "Buy" rating in Wednesday, July 12 report.

The Average Volume for 10 days is 4.54 Million for Verastem Inc (NASDAQ:VSTM). Verastem Inc (NASDAQ:VSTM)'s price to free cash flow for trailing twelve months is 0. 1,924,207 shares of the company traded hands.

The stock is now moving with a Positive distance from 200-Day Simple Moving Average of about 154.83% and has a pretty decent Year to Date (YTD) Performance of 265.18% which means the stock is constantly adding to its value from previous fiscal year end price. The company has market cap of $144.96 million.

While having a peek at profitability ratios Verastem Inc (NASDAQ:VSTM) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). On average, equities analysts predict that Verastem will post ($1.31) EPS for the current fiscal year.

Rémy annoncé à l'OM — Mercato Chelsea
Du côté de la L1, Rennes se serait également penché sur son cas, mais sans la moindre suite pour le moment. Personne n'en doutait vraiment, mais Loïc Rémy va bel et bien quitter Chelsea pendant l'intersaison.

WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of U.S. & global copyright & trademark legislation.

In related news, Director Timothy J. Barberich purchased 30,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were acquired at an average cost of $2.45 per share, with a total value of $73,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of large investors have recently modified their holdings of VSTM. FMR LLC boosted its stake in shares of Verastem by 32.2% in the fourth quarter. The institutional investor owned 373,420 shares of the biopharmaceutical company's stock after selling 700 shares during the period. Renaissance Technologies LLC boosted its position in shares of Verastem by 13.6% in the fourth quarter.

Let's take an assessment at how Verastem, Inc. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584.